A B S T R A C T Studies were undertaken in man to evaluate the roles of volume depletion and of the parathyroid glands in mediating the changes in serum and urinary calcium which follow the administration of hydrochlorothiazide, 100 mg twice daily, for 4 days. 42 studies were carried out in 16 normal subjects, 9 patients with hyperparathyroidism, and 7 vitamin D-treated subjects with hypoparathyroidism. In six studies in normal subjects, daily sodium losses during thiazide administration were quantitatively replaced, and in six other studies the effect of equivalent sodium losses produced by furosemide was evaluated.
INTRODUCTION
Diuretics of the benzothiadiazide (thiazide) group affect calcium metabolism by producing a fall in urinary calcium and, often, an increase in serum calcium concentration (1) (2) (3) (4) (5) (6) (7) (8) . The mechanisms whereby these drugs exert such actions are poorly understood. In a preliminary report, Suki, Hull, Rector, and Seldin (9) suggested that urinary calcium falls as a result of depletion of extracellular fluid volume (ECV)1 secondary to the sodium losses produced by the diuretic. However, other preliminary observations suggested that the fall in urinary calcium was in some way dependent upon nary excretion of calcium after the use of thiazide diuretics, indicating that the rise in serum calcium induced by thiazides is not due to the renal retention of calcium. Finally, experiments carried out in dogs have suggested that thiazide diuretics may directly produce parathyroid hyperplasia (13) .
The present study was undertaken to evaluate in man the roles of ECV depletion and of the parathyroid glands in mediating the changes in urinary and serum calcium which follow the administration of hydrochlorothiazide. 42 studies were carried out in 16 normal subjects, 9 patients with hyperparathyroidism, and 7 patients with hypoparathyroidism treated with vitamin D. The normal subjects were males, aged 24 -65 yr and free of detectable cardiovascular, metabolic, hepatic, or renal abnormalities. The group with hyperparathyroidism consisted of one female and eight males, aged yr. The diagnosis of hyperparathyroidism was made by the usual biochemical criteria (14) and was confirmed at surgery in six. The three unoperated patients exhibited hypercalcemia, hypophosphatemia, a low renal tubular reabsorption of phosphate, and responses to phosphate loading (15) and calcium infusion (16) , which were consistent with the diagnosis of hyperparathyroidism. The patients with hypoparathyroidism included two females and five males, aged yr. Hypoparathyroidism was idiopathic in two and resulted from surgery in 5 patients.
METHODS
In each, the diagnosis was established by the presence of hypocalcemia and hyperphosphatemia present for 6 months to several years before treatment with vitamin D. All had been receiving vitamin D2, 50,000-100,000 IU/day, and supplemental calcium, 1-2 g/day, for periods ranging betxveen 4 In six additional studies in normal subjects, the thiazideinduced sodium losses were replaced quantitatively by oral administration of sodium chloride. The quantity of supplemental salt given on the 1st day was estimated from the magnitude of sodium diuresis observed on the 1st day of thiazide treatment in other studies. During the subsequent 3 days, the daily dose of sodium was adjusted to maintain the subjects in sodium balance as estimated from intake and urinary losses during the previous day and from fluctuations in body weight measured three times daily. At the end of thiazide treatment, sodium supplementation was discontinued.
24-hr urines were collected throughout, and blood samples were obtained twice each day, before breakfast at 8 a.m. and again at 4 p.m. In additional studies not listed above (two in patients with hyperparathyroidism and two in patients with hypoparathyroidism treated with vitamin D) only blood samples were collected. Body weight was measured each morning before breakfast and after the patient had voided. Glomerular filtration rate (GFR) was estimated from endogenous creatinine clearance. Creatinine, sodium, calcium, and phosphorus in plasma and urine, and total protein and water content of plasma were measured by methods previously reported from this laboratory (17, 18) . The concentration of diffusible calcium in serum was measured in ultrafiltrates of serum prepared anaerobically (19) from eight patients with hyperparathyroidism before and on the 4th day of therapy with thiazides.
RESULTS
The effects of thiazide treatment, with and without supplemental sodium, and those of furosemide on creatinine clearance, urinary sodium, calcium, and phosphorus in all subjects are summarized in Table I . The results from a representative study in a normal subject are shown in Fig. 1 . In subjects not receiving supplemental salt, the administration of hydrochlorothiazide produced the expected increase in sodium excretion, return to control levels during the post-treatment period in all but one patient. Although the maximum absolute decrease in daily calcium excretion from the mean control value was greater in patients with hyperparathyroidism (217 ±42 mg/day) than in normals (97 +14 mg/day), the per cent decrement from control levels was not different. In contrast, the mean urinary calcium excretion did not decrease in patients with hypoparathyroidism; the excretion rates were 347 ±76 mg/day during the control period and 406 ±106 mg/day on the 4th day of thiazide administration. Moreover, no significant change in urinary calcium excretion occurred during the post-treatment period.
The mean endogenous creatinine clearance rate decreased significantly on the 4th day of thiazide therapy in normals and on the 3rd day in those with hyperparathyroidism; the effect was variable in the patients with hypoparathyroidism. Alterations in filtered calcium, estimated as the product of creatinine clearance and 62% of total plasma calcium, did not account for either the reduction in urinary calcium in normals and those with hyperparathyroidism or for the difference between the calcium excretion observed in patients with hypoparathyroidism and in the other two groups of subjects (Fig. 2) .
When thiazide-induced sodium losses were replaced When the drug was discontinued, serum calcium usually returned to or below the control levels. The concentration of plasma proteins increased during treatment with thiazides as a result of hemoconcentration, and the increased protein concentration should result in more protein-bound calcium. To adjust for changes in total plasma calcium resulting merely from alterations in protein-bound calcium, the total calcium levels were "corrected" for the change in plasma proteins according to a formula described by Parfitt (10) where it is assumed that plasma calcium is 60% diffusible and that the protein-bound fraction changes in proportion to the changes in the concentration of total protein. With such adjustments, the mean increases in "corrected" calcium levels with thiazide therapy were 0.19 ±0.099, 0.48 ±0.066, and 0.40 ±0.134 mg/100 ml in the normal subjects, and patients with hyper-and hypoparathyroidism, respectively. Moreover, in the patients with hyperparathyroidism where ultrafiltrable calcium levels were actually measured, these increased by 0.27 ±0.092 mg/100 ml (P < 0.025), a value which is approximately 60% of the "corrected" change in total calcium concentration. DISCUSSION Although previous studies have shown that the administration of hydrochlorothiazide to normal subjects and those with hyperparathyroidism causes a decrease in urinary calcium, the mechanisms(s) responsible for this phenomenon remains unclear. Urinary calcium represents the difference betweeil the quantity filtered at the glomeruli and that reabsorbed by the tubules. A decrease in the filtered load of calcium or an increase in the renal tubular reabsorption can produce a fall in urinary calcium. The results of other work (1, 3, 8) and of the present study show that the decrease in urinary calcium observed in normal subjects and in patients with hyperparathyroidism cannot be accounted for by a reduction in filtered calcium (Fig. 2) .
The renal tubular reabsorption of calcium is closely related to that of sodium (17, 18, 20, 21) , and it is likely that certain events promoting sodium transport in the nephron can also augment the reabsorption of calcium. Also, enhanced tubular reabsorption of calcium follows increased action of parathyroid hormone (22, 23) . Epstein reported that subjects receiving a diet low in sodium display a fall in their urinary calcium (24) . Further, Suki and coworkers suggested in a All data are mean ±SE. "Corrected" serum calcium is derived in a manner described in the text.
* Differs significantly from zero: P < 0.01.
X Differs significantlyfrom zero: P < 0.05.
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A. S. Brickman, S. G. Massry, and J. W. Coburn present study. Further, acute studies in man (25, 26) and dogs (27, 28) show that urinary calcium rises shortly after the administration of thiazides (28), although the increase in calcium excretion relative to that of sodium is small when compared to other diuretics such as furosemide, ethacrynic acid, and mercurial compounds (25, 26, 28) . This dissociation between urinary calcium and sodium with thiazides could be related to direct inhibition of sodium reabsorption at a site in the distal convoluted tubule where the transport of calcium and sodium are not closely associated or may be negatively related (29) . Low basal levels of urinary calcium could not be responsible for the failure of thiazides to cause a fall in calcium excretion in patients with hypoparathyroidism since the control rates of calcium excretion in these subjects were similar to or exceeded those of normals and the subjects with hyperparathyroidism. It is unlikely that treatment with large doses of vitamin D2 prevented a fall in urinary calcium in response to thiazide diuretic. Parfitt (10) reported a decrease in urinary calcium in a patient with idiopathic osteoporosis receiving vitamin D2, and we have observed a reduction in urinary calcium after thiazide administration in two normal subjects receiving vitamin D2, 50,000 IU/day (unpublished data). It appears, therefore, that parathyroid hormone must be present before thiazides cause a fall in urinary calcium. There is evidence that parathyroid hormone exerts renal action through activation of an adenyl cyclase system with the release of cyclic AMP (30) (31) (32) . Thiazides can inhibit phosphodiesterase (33, 34) , an enzyme which accelerates degradation of cyclic AMP. Therefore, in the presence of parathyroid hormone, thiazides might lead to increased renal concentrations of cyclic AMP and potentiate the action of the hormone. Such an augmentation of hormone action is suggested by our observations in two vitamin Dtreated patients with hypoparathyroidism who received two standardized infusions of parathyroid extract (PTE), first as a control and later on the 4th day of therapy with thiazides; in these two patients, the diuretic-induced sodium losses were not replaced. Urinary calcium fell by 17 and 43% with infusion of PTE alone and by 57 and 69% during the administration of PTE with thiazides in the two patients, respectively (unpublished observations). The increase in urinary phosphate in normals and in those with hyperparathyroidism and the absence of phosphaturia in patients with hypoparathyroidism with thiazide administration are also consistent with hydrochlorothiazide potentiating the action of parathyroid hormone. Eknoyan, Suki, and MartinezMaldonado (28) A rise in the level of serum calcium has been described in normal subjects receiving thiazides (3, 36) , and thiazides can cause overt hypercalcemia in patients with hyperparathyroidism (10, 3740) . It has been suggested that the use of thiazides may be of value in the diagnosis of primary hyperparathyroidism (39, 40) . In the present study, an increase in levels of total serum calcium was observed in normals, and in patients with hyper-and hypoparathyroidism during treatment with thiazides; moreover, hypercalcemia became evident in the two normocalcemic patients subsequently shown to have hyperparathyroidism. Overt hypercalcemia did not occur otherwise, except in one patient with hypoparathyroidism treated with vitamin D (Fig. 3) . Hypercalcemia has been reported during thiazide treatment in a patient receiving vitamin D (10) , and therapy with thiazides aggravated hypercalcemia in two patients with malignant disease (39) . These observations sug- gest that thiazides may induce hypercalcemia in patients with conditions associated with enhanced rates of bone resorption.
Several factors may be responsible for the increase in levels of plasma calcium. Hemoconcentration of plasma proteins probably accounts in part for the augmented serum calcium levels. However, after adjustment for changes in plasma protein, the "corrected" serum calcium levels were still significantly increased during thiazide therapy in patients with hyper-and hypoparathyroidism, while in normals, the "corrected" values were not significantly greater than controls. Also, plasma calcium did not change in the normal subjects when thiazide-induced sodium losses were replaced and hemoconcentration was prevented. The reduction in urinary calcium during thiazide treatment does not seem to be the primary factor contributing to the elevation of plasma calcium. Thus, serum calcium increased in patients with hypoparathyroidism while urinary calcium did not change, and previous data (12) have shown an increase in serum calcium in response to thiazide treatment in uremic patients with little or no urinary output. In addition, Parfitt (10) found no correlation between the change in serum calcium and the quantitative decrease in urinary calcium excretion.
It is possible that thiazides produce an increase in plasma calcium by enhancing the release of this ion from bone into the extracellular fluid. This augmented release might be achieved by a direct action on bone, by potentiation of the action of parathyroid hormone, or by enhancing bone resorption caused by other factors, e.g., vitamin D or malignant diseases.
Finally, the elevation in plasma calcium concentration could be produced by increased gastrointestinal absorption of calcium. In this regard, the available data arecontradictory: observations of enhanced calcium absorption have been described (8) and others have reported either unchanged or decreased absorption (2, 5, 41, 42) .
